(Q50579684)

15 March 2018

title

Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection. (English)

1 reference

15 March 2018

1 reference

1 reference

6

1 reference

15 March 2018

author name string

Sanjee Aora

1

1 reference

15 March 2018

Christine Xu

2

1 reference

15 March 2018

Alice Teng

3

1 reference

15 March 2018

Janet Peterson

4

1 reference

15 March 2018

Li-Tain Yeh

5

1 reference

15 March 2018

Daryl Lau

7

1 reference

15 March 2018

Stephen Rossi

8

1 reference

15 March 2018

Chin-chung Lin

9

1 reference

15 March 2018

publication date

1 March 2005

1 reference

15 March 2018

The Journal of Clinical Pharmacology

published in

1 reference

15 March 2018

volume

45

1 reference

15 March 2018

issue

3

1 reference

15 March 2018

page(s)

275-285

1 reference

15 March 2018

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270004270152

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004270152

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004270152

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004270152

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004270152

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004270152

Plasma disappearance, urine excretion, and tissue distribution of ribavirin in rats and rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004270152

Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004270152

The metabolism of ribavirin in erythrocytes and nucleated cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004270152

Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004270152

Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004270152

Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004270152

Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004270152

Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004270152

21 January 2018

Identifiers

DOI

10.1177/0091270004270152

1 reference

15 March 2018

1 reference

15 March 2018